For the quarter ended December 31, 2025, Apogee reported a net loss of 255843000 and an operating loss of 285595000, driven by research and development expenses of 214712000 and general and administrative expenses of 70883000. The company ended the year with 131549000 in cash and cash equivalents.

The company posted a wider quarterly net loss on higher R&D and G&A spending, maintained a strong $621.2M cash and securities balance, and highlighted positive APG777 Phase 2 Part A data with accelerated timelines for Part B.

Apogee Therapeutics reported a net loss of $55.3 million for Q1 2025, an increase from $32.1 million in Q1 2024, primarily due to higher R&D and G&A expenses. The company's cash position remains strong at $681.4 million, supporting operations into Q1 2028. Key pipeline advancements include progress in the APEX trial for APG777 in atopic dermatitis and positive interim data for APG808 in asthma.

Apogee Therapeutics reported full year 2024 financial results, highlighting the accelerated execution of the Phase 2 APEX clinical trial for APG777 and the positive interim Phase 1 results for APG990. The company's cash, cash equivalents, and marketable securities totaled $731.1 million, providing a runway into Q1 2028.

Apogee Therapeutics reported its Q3 2024 financial results, highlighting continued execution across all programs, including positive results from the APG777 Phase 1 trial. The company is on track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024, and interim Phase 1 data for APG990 in 1H 2025. Apogee had $753.8 million in cash, cash equivalents, and marketable securities, providing runway into 2028.

Apogee Therapeutics reported pipeline highlights and second quarter financial results, with a focus on advancing its pipeline, including APG777, APG808, and APG990, and adding APG333 to its portfolio. The company plans combination studies and has a cash runway into 2028.

Apogee Therapeutics reported its first quarter financial results, highlighting the initiation of a Phase 2 clinical trial for APG777, dosing of the first participant in the Phase 1 trial of APG808, and nomination of a development candidate for APG990. The company's cash runway extends into 2028, supported by $816 million in cash, cash equivalents and marketable securities.

Apogee Therapeutics reported a net loss of $31.7 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $395.5 million as of December 31, 2023, which is expected to fund operations into 4Q 2026.